试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-11-05
To Assess the Role of Fecal Microbiota Transplant in Acute Liver Failure
编号:NCT03363022登记状态:入组前撤回企业 / 申办者:Institute of Liver and Biliary Sciences, India
药物 / 成分:Standard Medical Treatment、Fecal Microbiota Transplant、Placebo
登记的停止原因(原文):Lack of Funds
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-11-05
Restrictive Versus Liberal Red Blood Cell Transfusion in Patients of Cirrhosis With Septic Shock
编号:NCT03433508登记状态:入组前撤回企业 / 申办者:Institute of Liver and Biliary Sciences, India
药物 / 成分:Liberal、Restrictive
登记的停止原因(原文):lack of funds
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-11-05
Comparison of Three Opioid Detoxification Treatment Regimens
编号:NCT03678792登记状态:入组前撤回企业 / 申办者:University of Alabama at Birmingham
药物 / 成分:Buprenorphine/naloxone、Morphine、Tramadol
登记的停止原因(原文):Infeasible to conduct at this time.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-11-04
A Study for Adolescents With Fibromyalgia Syndrome
编号:NCT01089621登记状态:入组前撤回企业 / 申办者:Eli Lilly and Company
药物 / 成分:Duloxetine
登记的停止原因(原文):Terminated due to study design changes; zero patients enrolled.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-11-04
L-tetrahydropalmatine (l-THP) Treatment for Cocaine Use Disorder
编号:NCT02139761登记状态:入组前撤回企业 / 申办者:University of Maryland, Baltimore
药物 / 成分:l-tetrahydropalmatine (l-THP)、Placebo
登记的停止原因(原文):Study funding has not been established
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-11-04
Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors
编号:NCT02538432登记状态:入组前撤回企业 / 申办者:University of Maryland, Baltimore
药物 / 成分:RQ-00000007、Gemcitabine
登记的停止原因(原文):PI No Longer at University of Maryland. Now at Fox Chase
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-11-04
High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit.
编号:NCT03115697登记状态:入组前撤回企业 / 申办者:Institute of Liver and Biliary Sciences, India
药物 / 成分:Lactulose、Rifaximin、Plasmapheresis
登记的停止原因(原文):lack of funds
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-11-01
Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients
编号:NCT01812434登记状态:入组前撤回企业 / 申办者:University of Minnesota
药物 / 成分:Sildenafil、Placebo
登记的停止原因(原文):PI Left University
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-11-01
Intranasal Oxytocin and Learning in Autism
编号:NCT02090829登记状态:入组前撤回企业 / 申办者:University of Minnesota
药物 / 成分:Syntocinon (synthetic oxytocin)、Placebo
登记的停止原因(原文):Low recruitment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-11-01
Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial.
编号:NCT02868164登记状态:入组前撤回企业 / 申办者:Institute of Liver and Biliary Sciences, India
药物 / 成分:Fecal Microbiota Transplantation、Standard Treatment、Weight Reduction
登记的停止原因(原文):lack of funds
查看官方原始记录 ↗